Zilurgisertib is a medicine for fibrodysplasia ossificans progressiva (FOP), a rare disease where muscles and other soft tissue slowly turn into bone. It blocks an overactive signal that tells the body to grow bone in the wrong places. It is taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Atebrioz (Zilurgisertib) for Myositis Ossificans?
Zilurgisertib, sold in the US as Atebrioz, is a prescription tablet for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease in which muscles, tendons and ligaments are gradually replaced by bone. This misplaced bone, called heterotopic ossification, can lock joints in place and steadily limit movement. It often forms during flare-ups, which can follow an injury such as a fall or a viral illness. Atebrioz was approved by the FDA in 2026 to reduce the amount of new abnormal bone that forms in adults and children 12 and older with FOP. It has not been studied enough in children under 12 to know whether it is safe or effective for them. The other approved option is palovarotene (Sohonos), a medicine related to vitamin A that can be used from age 8 in girls and age 10 in boys. Neither medicine removes bone that has already formed, so the aim of treatment is to slow further loss of movement.
Bone growth is controlled by signals that tell cells when and where to make bone. One of the switches in this system is a receptor called ALK2 (activin receptor-like kinase-2). In FOP, a change in ACVR1, the gene that carries the instructions for ALK2, leaves the switch stuck partly on, so tissue that should stay soft can be turned into cartilage and then bone. Zilurgisertib blocks ALK2, turning down that overactive signal. In studies, this reduced the process by which soft tissue is converted into bone. It does not repair the underlying gene change, so its effect depends on taking it continuously.
Atebrioz comes as 25 mg tablets. The usual dose is 100 mg (four tablets) once a day, with or without food. People who cannot swallow tablets can crush the four tablets and mix them into about 4 tablespoons of water, orange juice, apple sauce or plain yogurt, then take the mixture right away rather than saving it for later. Avoid grapefruit, pomelo and juices that contain them, because they can raise the amount of medicine in the blood. If someone also needs a strong blocker of the liver enzyme CYP3A4, such as the antifungal itraconazole, the antibiotic clarithromycin or the HIV booster ritonavir, the prescriber lowers the dose to 50 mg a day. Don't change the dose or stop on your own without talking with the prescriber.
In the main trial, the most common side effects were headache, joint pain, colds or sinus infections, nosebleeds and nausea. Each affected roughly one in five people or fewer, and slightly more often than with a placebo (dummy pill). Less often, people had stomach upset, acid reflux, rash, hair thinning or low iron levels. Blood tests in the trial also showed average rises in iron and hemoglobin (the oxygen-carrying protein in red blood cells). These stayed within the normal range and were not linked to signs of iron overload through about two years of follow-up.
Zilurgisertib can seriously harm an unborn baby and must not be taken during pregnancy. Anyone who could become pregnant needs a pregnancy test before starting and should use effective birth control during treatment and for one week after the last dose. If pregnancy occurs or is suspected, stop the medicine and call the prescriber right away. Breastfeeding is not recommended during treatment or for at least one week after the last dose, because the medicine could affect a baby's bone development. Several medicines change how zilurgisertib works. Drugs that speed up the CYP3A4 enzyme, including the seizure medicines carbamazepine and phenytoin, the tuberculosis antibiotic rifampin and the herbal supplement St. John's wort, can lower its levels enough to make it less effective and should be avoided. Zilurgisertib can also raise levels of metformin, a common diabetes medicine, so the two are generally not combined. Tell the prescriber and pharmacist about every prescription, over-the-counter medicine and supplement you take.
Zilurgisertib does not usually produce changes a person can feel day to day. Its benefit is measured as less new bone forming over time, which doctors track with whole-body CT (computed tomography) scans. In the trial that led to approval, 63 people aged 12 to 64 took zilurgisertib or a placebo for six months. On average, people on placebo formed about 25 cubic centimeters of new abnormal bone, roughly the volume of five teaspoons, while those on zilurgisertib formed essentially none. Results varied between people, and the trial did not show whether this protects movement or prevents flare-ups over many years. The medicine is meant to be taken long term, and the trial's open-label extension is still following people. Long-term safety is not fully known. In animal studies, rats given zilurgisertib built up iron in the liver and showed cell changes that could be early signs of cancer; whether this matters for people is uncertain, and no long-term cancer studies have been done. The medicine does not replace the everyday FOP precautions: falls, muscle injuries and invasive medical procedures can still trigger flare-ups and new bone.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Atebrioz (Zilurgisertib), what you've noticed, or ask the community a question.